ICTI Completes Implementation of Tech-Support Software: IncidentMonitor TM

December 23, 2005

Thursday, 22 December 2005, Interactive Clinical Technologies Inc. (ICTI) is pleased to announce the successful implementation of Incident Monitor, ™ ICTI’s latest system support infrastructure enhancement.  Incident Monitor ™ is an electronic call tracking application that is used to track end user support calls from ring to resolution.

The Incident Monitor ™ application further strengthens the service provided by ICTI’s in-house 24 hours per day, 7 days per week Technical Support Center by enabling efficient electronic tracking and metric generation for system support calls.   The ability to efficiently capture and extract metrics makes it possible for ICTI to quickly identify recurring patterns on a study and provide clients with timely feedback that can be used to improve the effectiveness of the clinical trial.

About ICTI and Almac Sciences

ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; iDiary phone-based patient diaries; iTrial EDC for electronic case report form data collection; and iForecasting for clinical trial materials planning.

Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDx (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.

Contact Jim Murphy or Meghan Adams US: 267-685-4284

[email protected]


Back to news